Dizal Leads China’s Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO

Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib (JACKPOT8) Sunvozertinib achieved an ORR of 60.8% in ≥ second-line treatment and 77.8% in the first-line treatment for EGFR Exon20ins NSCLC Sunvozertinib demonstrated durable benefit in advanced NSCLC patients with TKI-resistant EGFR sensitizing mutations with a … Read more

Dizal’s Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting

SHANGHAI, May 25, 2023 /PRNewswire/ — Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal’s two leading assets – sunvozertinib (a selective EGFR TKI targeting a wide … Read more